Stockreport

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

Tenax Therapeutics, Inc.  (TENX) 
Last tenax therapeutics, inc. earnings: 11/14 04:31 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.tenaxthera.com
PDF Amendment to Enlarge Phase 3 LEVEL Study, Increasing Statistical Powering, Accepted by FDA, Expected to be Fully Enrolled Around Year End 2025 Agreement by FDA to Initi [Read more]